Nexstim

8.79 EUR

+2.93%

5,649 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

+2.93 %
-3.93 %
-32.12 %
-38.10 %
-39.38 %
+12.12 %
+144.85 %
+67.43 %
-98.55 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
70.98M EUR
Turnover
58.88K EUR
P/E (adj.) (26e)
70.38
EV/EBIT (adj.) (26e)
56.94
P/B (26e)
6.94
EV/S (26e)
5.41
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
14.05.2026
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Forum discussions
The company is doing great, and this year will likely be its best year in history, including in terms of growth. Capital-intensive investments in medical devices just tend to be concentrated towards the end of the year, so now we are just waiting, and some have better nerves than...
Agreed, the vibe is good. Nothing has changed from the 16 prices. Perhaps there was an expectation that Brainlab’s impact would start sooner, leading to some gloominess. In fact, the beginning of the year has gone quite swimmingly, and I believe a good purpose has been planned for...
Perhaps they do not wish to disclose more details at this stage, but the following comment from CEO Karvinen outlines the rough plan: “thereby strengthening the Company’s financial position for the next phases in the execution of our profitable growth strategy.”
I have a small speculative position myself, but I don’t view this as the “sure thing” that many here are advertising. The stock price still factors in quite a bit of positivity already. And even though approvals have been secured, devices are in use worldwide, and positive results...
Here is the previously published article regarding that aimbot technology https://www.aalto.fi/fi/uutiset/uuden-sukupolven-magneettistimulaatio-voi-mullistaa-aivosairauksien-hoidon
Well, at least the bench is Nexstim’s The message must be 50 characters long.
Printing new shares doesn’t please all investors either, especially when the reason isn’t really explained.
Read more on our forum